Phenomenon of hormone-dependent polyneoplasia of the female reproductive system

Cover Page

Cite item

Full Text

Abstract

BACKGROUND: Primary multiplicity of malignant tumors of the female reproductive system is the least studied area of clinical oncology. In addition, the steady rise in the number of patients and various localizations of polyneoplasia with lesions of the female reproductive organs necessitate a detailed study of this problem.

AIM: This study aimed to determine the incidence and risk factors and describe the clinical aspects of polyneoplasia of the female reproductive system for 2010–2021 in women seen at the Medical and Rehabilitation Center of the Ministry of Health of Russia, Moscow, and the University Clinical Hospital No. 4 of the I.M. Sechenov First Moscow State Medical University.

MATERIALS AND METHODS: We conducted a retrospective analysis of the case records of 147 patients with a confirmed diagnosis of polyneoplasia of the female reproductive system for 2010–2021, which accounted for 3.6% of all newly diagnosed neoplasms of the female reproductive system in the above medical institutions. Moreover, a continuous sampling method was used.

RESULTS: Breast cancer was the most frequent first tumor, combined with cancer of the contralateral breast in 27 (42.1%) patients, cancer of the uterine body in 4 (6.25%) patients, ovarian cancer in 4 (6.25%) patients, colon cancer in 4 (6.25%) patients, and thyroid cancer in 1 (1.5%) patient. Cancer of the uterine body was combined with breast cancer in 10 (35.7%) patients, ovarian cancer in 2 (7.1%) patients, thyroid cancer in 2 (7.1%) patients, and colon cancer in 3 (11.1%) patients. Endometrioid adenocarcinoma, pathogenic variant I was determined in 20 (71.4%) cases according to the histological structure. Thyroid cancer was detected in 7 (5.6%) cases; in all cases, it developed metachronously, and it was combined as the initial tumor with breast cancer in 1 (14.3%) case, uterine body cancer in 2 (28.5%) cases, and ovarian cancer in 1 (14.3%) case. As the second tumor, it was also combined with uterine body cancer in 2 (28.5%) cases and ovarian cancer in 1 (14.3%) case. The risk factors assessment led to the identification of several factors that are common in patients with hormone-dependent forms of primary multiple cancer, including obesity, diabetes mellitus, irregular menstrual cycle, history of proliferative diseases of the mammary glands, intake of thyroid drugs, uterine hyperplastic processes, and hypothyroidism.

CONCLUSIONS: Understanding the different aspects of the development and course of hormone-dependent polyneoplasia of the female reproductive system will help in developing approaches for follow-up monitoring of women who have been treated for a primary tumor and are at risk of developing a subsequent tumor of hormone-dependent organs, to prevent the recurrence of the disease and predict the subsequent tumor and ensure its timely detection.

About the authors

Lidiya A. Klyukina

I.M. Sechenov First Moscow State Medical University

Author for correspondence.
Email: lidiaklyukina@mail.ru
ORCID iD: 0000-0001-7602-4584

Post-Graduate Student

Russian Federation, Moscow

Elena A. Sosnova

I.M. Sechenov First Moscow State Medical University

Email: sosnova-elena@inbox.ru
ORCID iD: 0000-0002-1732-6870
SPIN-code: 6313-9959

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Anton A. Ishchenko

Medical and Rehabilitation Center

Email: ra2001_2001@mail.ru
ORCID iD: 0000-0001-6673-3934

MD, Cand. Sci. (Med.)

Russian Federation, Moscow

Mikhail M. Davydov

I.M. Sechenov First Moscow State Medical University

Email: mihail-davydov@mail.ru
ORCID iD: 0000-0001-5038-9307

MD, Dr. Sci. (Med.), Corresponding Member of the Russian Academy of Sciences, Head of the Department of Oncology

Russian Federation, Moscow

References

  1. Davydov MI, Aksel’ EM, editors. Statistika zlokachestvennykh novoobrazovanii v Rossii i stranakh SNG v 2012 g. Moscow; 2014. (In Russ).
  2. Kaprin AD, Starinskii VV, Shakhzadova AO, editors. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2021 godu. Moscow: P.A. Herzen Moscow Research Oncological Institute ― branch of the National Medical Research Center of Radiology; 2022. (In Russ).
  3. Ibrahim M, Saleh M, Ali A., et al. Multiple Primary Malignant Neoplasms: An Unusual Case of Metachronous Breast Ductal and Squamous Cell Carcinomas. Cureus. 2020;12(2):e6954. doi: 10.7759/cureus.6954
  4. Petrov NN, ed. Zlokachestvennye opukholi. Rukovodstvo v 3 tomakh. Vol. 1. Leningrad: Medgiz; 1947. 480 p. (In Russ).
  5. Zisman IF, Kirichenko GD. Klinicheskie aspekty pervichnoi mnozhestvennosti zlokachestvennykh novoobrazovanii. Chisinau: Stiinza; 1978. (In Russ).
  6. Tasca G, Dieci MV, Baretta Z, et al. Synchronous and Metachronous Breast and Ovarian Cancer: Experience From Two Large Cancer Center. Front Oncol. 2020;10:608783. doi: 10.3389/fonc.2020.608783
  7. Aydiner A, Karadeniz A, Uygun K, et al. Multiple primary neoplasms at asingle institution: differences between synchronous and metachronous neoplasms. Am J Clinical Oncology. 2000;23(4):364–370. doi: 10.1097/00000421-200008000-00011
  8. Woodruff JD, Solomon D, Sullivant H. Multifocal disease in the upper genital canal. Obstet Gynecol. 1985;65:695–698.
  9. Song T, Seong SJ, Bae DS, et al. Prognostic factors in women with synchronous endometrial and ovarian cancers. Int J Gynecol Cancer. 2014;24(3):520–527. doi: 10.1097/IGC.0000000000000073
  10. Maksimov SYa. Pervichno-mnozhestvennye opukholi organov reproduktivnoi sistemy. Practical oncology. 2009;10(2):117–123. (In Russ).
  11. Behtereva SA, Vazhenin AV, Domozhirova AS, Iaĭtsev SV. The incidence and pathogenetic types of multiple primary endometrial cancer in the Chelyabinsk region. P.A. Herzen Journal of Oncology. 2018;7(3):3841. (In Russ). doi: 10.17116/onkolog20187338
  12. Tong SY, Lee YS, Park JS, et al. Clinical analysis of synchronous primary neoplasms of the female reproductive tract. Eur J Obstet Gynecol Reprod Biol. 2008;136:78–82. doi: 10.1016/j.ejogrb.2006.09.010
  13. Kutalia PZ, Selchuk VYu, Payanidi YuG, et al. Ovarian malignancies and polyneoplasias: clinical presentation, diagnosis, mechanisms of development, prognosis. Tumors of female reproductive system. 2011;(1):80–85. (In Russ). doi: 10.17650/1994-4098-2011-0-1-80-85
  14. Bekhtereva SA, Domozhirova AS, Aksenova IA, Pshichenko SV. Primary-multiple ovarian cancer. Theses of the III National Congress “Oncology of reproductive organs: from prevention and early detection to effective treatment”. May 31–June 2, 2018; Moscow. Research’n PractIcal Medicine Journal. 2018;5 Special Issue 1:20. (In Russ). doi: 10.17709/2409-2231-2018-5-S1
  15. Ayhan A, Gultekin M, Dursun P. Textbook of gynecological oncology. Gunes Publishing; 2009.
  16. Takatori E, Shoji T, Miura Y, et al. Triple simultaneous primary invasive gynecological malignancies: a case report. J Obstet Gynaecol Res. 2014;40(2):627–631. doi: 10.1111/jog.12199
  17. Kim CJ, Um SJ, Kim TY, et al. Regulation of cell growth and HPV genes by exogenous estrogen in cervical cancer cells. Int J Gynecol Cancer. 2000;10:157–164. doi: 10.1046/j.1525-1438.2000.00016.x
  18. Watrowski R, Striepecke E, Jäger C, Bauknecht T, Horst C. Papillary-serous adenocarcinoma of the uterine cervix during tamoxifen therapy after bilateral breast cancer. Anticancer Res. 2012;32:5075–5078.
  19. Sharma N, Thiek JL, Rituparna D, et al. Metachronous Cancer of Breast and Adenocarcinoma of Cervix: A Rare Case Report. J Menopausal Med. 2017;23(2):131–134. doi: 10.6118/jmm.2017.23.2.131
  20. Heng B, Glenn WK, Ye Y, et al. Human papilloma virus is associated with breast cancer. Br J Cancer. 2009;101(8):1345–1350. doi: 10.1038/sj.bjc.6605282
  21. Hennig EM, Suo Z, Thoresen S, et al. Human papillomavirus 16 in breast cancer of women treated for high grade cervical intraepithelial neoplasia (CIN III). Breast Cancer Res Treat. 1999;53:121–135. doi: 10.1023/a:1006162609420
  22. Payanidi YuG, Jordania KI, Pauker V, Selchuk VYu, Kazubskaya TP. Primary multiple malignant neoplasms bodies reproductive system and colon in women. Journal of NN Blokhin Russian Cancer Research Center. 2016;27(2):109–112. (In Russ).
  23. De Carolis С, Greco E, Guarino М. Antityroid antibodies and antiphospholipid syndrome: evidence of reduced fecundity and of poor pregnancy outcome in recurrent spontaneous abortions. Am J Reprod Immunol. 2004;52(4):263–266. doi: 10.1111/j.1600-0897.2004.00215.x
  24. Guseinova NF, Kurbanova DF, Mammedgasanov RM. Algorithm of management of patients with polycystic ovary syndrome in combination with various thyroid diseases. Obstetrics and Gynecology. 2009;(3):71–72. (In Russ).
  25. Mayorov MV. Thyroid gland and female reproductive health. Provizor. 2007;(22):21–24. (In Russ).
  26. Bokhman YaV. Guide to oncogynecology. Leningrad: Meditsina; 1989. (In Russ).
  27. Hu X, Li D, Zhang W, et al. Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion. Arch Gynecol Obstet. 2012;286(6):1537–1543. doi: 10.1007/s00404-012-2456-6
  28. Shinderman-Maman E, Cohen K, Weingarten C, et al. The thyroid hormone ― avb3 integrin axis in ovarian cancer: regulation of gene transcription and MAPK-dependent proliferation. Oncogene. 2016;35(15):1977–1987. doi: 10.1038/onc.2015.262
  29. Afanas’yeva ZA, Bakunin SF, Petrov SV. Clinical and morphological features of polyneoplasias with thyroid lesions. Medical Almanac. 2010;(3):66–70. (In Russ). doi: 10.19181/snsp.2019.7.2.6410
  30. Cho JY, Léveillé R, Kao R, et al. Hormonal regulation of radioiodide uptake activity and Na+/I- symporter expression in mammary glands. J Clin Endocrinol Metab. 2000;85(8):2936–2943. doi: 10.1210/jcem.85.8.6727
  31. Wapnir IL, van de Rijn M, Nowels K, et al. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab. 2003;88(4):1880–1888. doi: 10.1210/jc.2002-021544
  32. Eskin BA, Parker JA, Bassett JG, George DL. Human breast uptake of radioactive iodine. Obstet Gynecol. 1974;44(3):398–402.
  33. Silva-Vieira M, Vaz SC, Esteves S, et al. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role? Thyroid. 2017;27(8):1068–1076. doi: 10.1089/thy.2016.0655
  34. Rappaport J. Changes in Dietary Iodine Explains Increasing Incidence of Breast Cancer with Distant Involvement in Young Women. J Cancer. 2017;8(2):174–177. doi: 10.7150/jca.17835
  35. Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101(12):1689–1693. doi: 10.1016/j.amjcard.2008.02.056
  36. Yang H, Holowko N, Grassmann F, et al. Hyperthyroidism is associated with breast cancer risk and mammographic and genetic risk predictors. BMC Med. 2020;18(1):225. doi: 10.1186/s12916-020-01690-y
  37. Kim EY, Chang Y, Lee KH, et al. Serum concentration of thyroid hormones in abnormal and euthyroid ranges and breast cancer risk: A cohort study. Int J Cancer. 2019;145(12):3257–3266. doi: 10.1002/ijc.32283
  38. Tang HY, Lin HY, Zhang S, et al. Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology. 2004;145(7):3265–3272. doi: 10.1210/en.2004-0308
  39. Tran T-V, Maringe C, Benitez Majano S, et al. Thyroid dysfunction and breast cancer risk among women in the UK Biobank cohort. Cancer Med. 2021;10:4604–4614. doi: 10.1002/cam4.3978
  40. Cleary MP, Grossmann ME. Minireview: Obesity and breast cancer: the estrogen connection. Endocrinology. 2009;150(6):2537–2542. doi: 10.1210/en.2009-0070
  41. Weng CH, Okawa ER, Roberts MB, et al. Breast cancer risk in postmenopausal women with medical history of thyroid disorder in the women’s health initiative. Thyroid. 2020;30(4):519–530. doi: 10.1089/thy.2019.0426
  42. Yuan Sh, Kar S, Vithayathil M, et al. Causal associations of thyroid function and dysfunction with overall, breast and thyroid cancer: A two-sample Mendelian randomization study. Int J Cancer. 2020;147(7):1895–1903. doi: 10.1002/ijc.32988
  43. Zara-Lopes T, Gimenez-Martins APA, Nascimento-Filho CHV, et al. Role of MTHFR C677T and MTR A2756G polymorphisms in thyroid and breast cancer development. Genet Mol Res. 2016;15(2). doi: 10.4238/gmr.15028222
  44. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010;15(6):556–565. doi: 10.1634/theoncologist.2009-0285
  45. Shin HY, Jee YoH, Cho ER. Body mass index and incidence of thyroid cancer in Korea: the Korean cancer prevention study-II. J Cancer Res Clin Oncol. 2016;143(1):143–149. doi: 10.1007/s00432-016-2261-x
  46. Clavel-Chapelon F, Guillas G, Tondeur L, Kernaleguen C, Boutron-Ruault MC. Risk of differentiated thyroid cancer in relation to adult weight, height and body shape over life: the French E3N cohort. Int J Cancer. 2010;126:2984–2990. doi: 10.1002/ijc.25066
  47. Romanchishen AF, Vabalaite KV. Primary-multiple tumors in patients with neoplasms of thyroid gland. Grecov’s Bulletin of Surgery. 2015;174(2):70–76. (In Russ). doi: 10.24884/0042-4625-2015-174-2-70-764
  48. Ahmed F, Goodman MT, Kosary C, et al. Excess risk of subsequent primary cancers among colorectal carcinoma survivors, 1975–2001. Cancer. 2006;107(5 Suppl.):1162–1171. doi: 10.1002/cncr.22013
  49. Afanas’eva ZA, Bakunin SF. The risk of development of multiple primary malignant tumors involving the thyroid gland. Kazan medical journal. 2012;93(4):616–623. (In Russ). doi: 10.17816/KMJ1555616–623.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Klyukina L.A., Sosnova E.A., Ishchenko A.A., Davydov M.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».